Novartis to Acquire Cadent Therapeutics for ~$770M

 Novartis to Acquire Cadent Therapeutics for ~$770M

Novartis to Acquire Cadent Therapeutics for ~$770M

Shots:

  • Novartis to acquire all outstanding shares of Cadent for a total value of ~$770M. Cadent to receive $210M up front and is eligible for ~$560M as milestones. The transaction is expected to be close in Q1’21
  • Novartis gains full rights to Cadent’s NMDAr program which consist of two clinical programs: CAD-9303 and MIJ-821, an NMDAr negative allosteric modulator that was licensed to Novartis in 2015
  • Additionally, Novartis gains Cadent’s pre-clinical programs and clinical stage (CAD-1883) movement disorder program

Click here ­to­ read full press release/ article | Ref: Novartis | Image: PRNewswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post